Hims & Hers: Q1 Confirms Margin Squeeze, 'Dead Money' Until Transition Proves

What happened

Hims & Hers Health's Q1 2026 results revealed a sharp margin compression, with gross margin falling to 65% from 73% and a net loss of $92.1 million, driven by inventory write-downs and the shift from compounded to branded GLP-1 drugs. Subscriber growth slowed to 9% year-over-year, while monthly revenue per subscriber declined from $85 to $80, signaling weakening monetization and reduced platform spending. Management raised FY2026 revenue guidance to $2.89 billion and highlighted international momentum, but the market remains skeptical given the underlying unit economics and the regulatory overhang. The company faces a disclosed DOJ referral and an FDA statement explicitly naming HIMS, creating material legal tail risk that overshadows the branded GLP-1 pivot. Until Q2 results demonstrate sustained branded GLP-1 throughput and margin stabilization, the stock is likely dead money, as the transition costs and competitive moat erosion weigh on valuation.

Implication

Investors should wait for the Q2'26 report (due August 2026) as the first full quarter of the new strategy; a miss on revenue or EBITDA guidance, or any disclosed enforcement action from the DOJ or FTC, would likely trigger another leg down. The risk/reward is unfavorable at $25 with an EV/EBITDA of 40x and no clear catalyst for multiple expansion until the legal and operational uncertainties resolve.

Thesis delta

The thesis has shifted from a growth story underpinned by compounding to a high-risk transition story dependent on branded GLP-1 economics and regulatory clearance. Our previous WAIT rating assumed the pivot could be managed, but Q1 results confirm the margin damage is real and subscriber monetization is deteriorating faster than expected. Until Q2 shows stabilization, the downside risks from legal action and continued margin compression outweigh any potential upside from the branded ramp.